Vanguard Group
PAND

Vanguard Group’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Vanguard Group’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-572,897
Closed -$34.4M – 4495
2021
Q1 		$34.4M Buy
572,897
+99,262
+21% +$3.59M ﹤0.01% 2510
2020
Q4 		$7.03M Buy
473,635
+154,484
+48% +$2.15M ﹤0.01% 3173
2020
Q3 		$3.66M Buy
+319,151
New +$5.45M ﹤0.01% 3294

Vanguard Group's PAND Position: Q2 2021 in Review

Vanguard Group sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 572,897 shares — an estimated $34.4M sold.

Vanguard Group first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $34.4M in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • Vanguard Group reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Vanguard Group sold 572,897 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $34.4M.
  • Vanguard Group first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Vanguard Group's Pandion Therapeutics Inc. Common Stock position peaked at $34.4M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Vanguard Group's 13F filing for Q2 2021, filed 13 Aug 2021.